ANTHONY W. IRELAND, M.B.; JOHN S. CLUBB, M.B.; FRANCIS C. NEALE, PH.D.; SOLOMON POSEN, M.D., F.R.A.C.P.; THOMAS S. REEVE, M.B.
This content is PDF only. Please click on the PDF icon to access.
Thirty patients with surgical hypoparathyroidism are presented. All received vitamin D therapy in the form of calciferol. Biochemical control, as defined by arbitrary criteria, was achieved in only nine patients for a total period of 26 patient-years.
The mean controlling dose of calciferol was 2.12 mg/day; the mean dose producing hypercalcemia in 16 patients was 3.28 mg/day. No patient was controlled on less than 1.25 mg/day, and only two patients were controlled on a calciferol dose of 1.25 mg/day. Every patient receiving calciferol doses greater than 2.50 mg/day became hypercalcemic. A mechanism is suggested for the proximity between "controlling" and "intoxicating" doses of calciferol in hypoparathyroidism. The documented periods of hypercalcemia lasted 1 to 6 weeks after withdrawal of calciferol.
No significant differences were found between the calciferol requirements of euthyroid and hypothyroid patients.
IRELAND AW, CLUBB JS, NEALE FC, POSEN S, REEVE TS. The Calciferol Requirements of Patients with Surgical Hypoparathyroidism. Ann Intern Med. ;69:81–89. doi: 10.7326/0003-4819-69-1-81
Download citation file:
Published: Ann Intern Med. 1968;69(1):81-89.
Endocrine and Metabolism, Parathyroid Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use